Pheochromocytoma and Paraganglioma
暂无分享,去创建一个
[1] F. Beuschlein,et al. Pheochromocytoma and paraganglioma: Clinical feature based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. , 2019, European journal of endocrinology.
[2] J. Langenhuijsen,et al. Pheochromocytoma and Pregnancy. , 2019, Endocrinology and metabolism clinics of North America.
[3] W. Young,et al. Impact of 123 I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma. , 2019, The Journal of clinical endocrinology and metabolism.
[4] W. Young,et al. Pheochromocytoma and Paraganglioma. , 2019, The New England journal of medicine.
[5] W. Young,et al. Pheochromocytoma Characteristics and Behavior Differ Depending on Method of Discovery. , 2018, The Journal of clinical endocrinology and metabolism.
[6] F. Beuschlein,et al. Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. , 2018, Clinical chemistry.
[7] A. Tabarin,et al. CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma , 2018, The Journal of clinical endocrinology and metabolism.
[8] F. Beuschlein,et al. Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging , 2018, Endocrine connections.
[9] T. Links,et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. , 2018, European journal of internal medicine.
[10] S. Bornstein,et al. Hypertensive crisis in pregnancy due to a metamorphosing pheochromocytoma with postdelivery Cushing's syndrome , 2018, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[11] H. Falhammar,et al. Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center , 2017, Endocrine connections.
[12] T. Bednarczuk,et al. Comparison of phenoxybenzamine and doxazosin in perioperative management of patients with pheochromocytoma. , 2017, Kardiologia polska.
[13] B. Klink,et al. Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas , 2017, The Journal of clinical endocrinology and metabolism.
[14] M. Razavi,et al. Pheochromocytoma and stress cardiomyopathy: Insight into pathogenesis , 2017, World journal of cardiology.
[15] O. Dekkers,et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. , 2016, European journal of endocrinology.
[16] A. Soltani,et al. Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms , 2016, Journal of Diabetes & Metabolic Disorders.
[17] Elise M. Blanchet,et al. Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma , 2015, Clinical Cancer Research.
[18] R. Hicks,et al. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.
[19] M. Fassnacht,et al. Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. , 2015, European journal of endocrinology.
[20] K. Pacak,et al. Pheochromocytoma and paraganglioma. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[21] F. Bidault,et al. Screening in asymptomatic SDHx mutation carriers: added value of 18F-FDG PET/CT at initial diagnosis and 1-year follow-up , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[22] A. Gimenez-Roqueplo,et al. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine , 2015, Nature Reviews Endocrinology.
[23] K. Pacak,et al. Should every patient diagnosed with a phaeochromocytoma have a 123I‐MIBG scintigraphy? , 2014, Clinical endocrinology.
[24] W. Young,et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.
[25] Richard Sinnott,et al. Biochemical diagnosis of phaeochromocytoma using plasma‐free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions , 2014, Clinical endocrinology.
[26] F. Beuschlein,et al. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatographytandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma , 2013, Annals of clinical biochemistry.
[27] J. Lenders,et al. Mortality Associated with Phaeochromocytoma , 2013, Hormone and Metabolic Research.
[28] A. Villringer,et al. Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma , 2013, Annals of clinical biochemistry.
[29] S. Bornstein,et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. , 2012, European journal of cancer.
[30] H. Dralle,et al. Perioperative Management of Pheochromocytoma/Paraganglioma: Is There a State of the Art? , 2012, Hormone and Metabolic Research.
[31] K. Pacak,et al. Current and Future Anatomical and Functional Imaging Approaches to Pheochromocytoma and Paraganglioma , 2012, Hormone and Metabolic Research.
[32] M. Fassnacht,et al. Long-term Postoperative Follow-up in Patients with Apparently Benign Pheochromocytoma and Paraganglioma , 2012, Hormone and Metabolic Research.
[33] J. Lenders,et al. Pheochromocytoma and pregnancy: a deceptive connection. , 2012, European journal of endocrinology.
[34] L. Hofbauer,et al. Pheochromocytoma – update on disease management , 2012, Therapeutic advances in endocrinology and metabolism.
[35] F. Messerli,et al. Takotsubo-like cardiomyopathy in pheochromocytoma. , 2011, International journal of cardiology.
[36] J. Lenders,et al. Cardiovascular manifestations of phaeochromocytoma , 2011, Journal of hypertension.
[37] S. Bornstein,et al. Surgery: Risks of hemodynamic instability in pheochromocytoma , 2010, Nature Reviews Endocrinology.
[38] G. Rasp,et al. Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. , 2009, Cancer research.
[39] W. Manger. The vagaries of pheochromocytomas. , 2005, American journal of hypertension.
[40] P. Munson,et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. , 2004, Endocrine-related cancer.
[41] C. Eng,et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.
[42] J. Schipper,et al. Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.
[43] F. Messerli,et al. Clinical and Experimental Pheochromocytoma , 1997 .
[44] K. Hirota,et al. Pheochromocytoma with Electrocardiographic Change Mimicking Angina Pectoris, and Cyclic Change in Direct Arterial Pressure—A Case Report , 1991, Angiology.
[45] K. Pacak,et al. Adverse Drug Reactions in Patients with Phaeochromocytoma , 2007, Drug safety.
[46] R. Reznek,et al. CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas) , 2004, European Radiology.
[47] PHÆOCHROMOCYTOMA , 1954, Journal of the Indian Medical Association.